Llwytho...
Novel antidotes for target specific oral anticoagulants
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing cl...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Exp Hematol Oncol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570637/ https://ncbi.nlm.nih.gov/pubmed/26380149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-015-0020-3 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|